NASDAQ:FDMT 4D Molecular Therapeutics (FDMT) News Today $18.55 -0.67 (-3.49%) (As of 02:28 PM ET) Add Compare Share Share Today's Range$18.38▼$19.9550-Day Range$15.16▼$21.8152-Week Range$5.32▼$26.49Volume222,280 shsAverage Volume464,720 shsMarket Capitalization$616.97 millionP/E RatioN/ADividend YieldN/APrice Target$34.13 HeadlinesProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address FDMT Media Mentions By Week FDMT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FDMT News Sentiment▼0.950.51▲Average Medical News Sentiment FDMT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FDMT Articles This Week▼62▲FDMT Articles Average Week All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAndreas Halvorsen's Firm Storms Deeper Into 4D Molecular Therapeuticsfinance.yahoo.com - June 7 at 1:13 PM4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Scott Bizily Sells 2,247 Sharesamericanbankingnews.com - June 7 at 7:28 AM4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Rating of "Moderate Buy" from Analystsmarketbeat.com - June 6 at 5:50 AMCitigroup Inc. Grows Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)marketbeat.com - June 5 at 4:52 AM4D Molecular Therapeutics Inc Ordinary Sharesmorningstar.com - June 3 at 10:02 AMPeloton Wealth Strategists Has $822,000 Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)marketbeat.com - June 2 at 2:39 PMOpaleye Management Inc. Has $7.33 Million Stock Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)marketbeat.com - May 26 at 2:50 PM4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meetingfinance.yahoo.com - May 24 at 12:23 PM4D Molecular Therapeutics (FDMT) Gets a Buy from BMO Capitalmarkets.businessinsider.com - May 24 at 7:23 AM4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down to $17.82americanbankingnews.com - May 18 at 6:34 AMQ2 2023 Earnings Estimate for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Issued By HC Wainwrightamericanbankingnews.com - May 16 at 2:30 AM4D Molecular Therapeutics, Inc. Expected to Post Q2 2023 Earnings of ($0.89) Per Share (NASDAQ:FDMT)marketbeat.com - May 15 at 2:22 AMAnalysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $34.13americanbankingnews.com - May 15 at 1:50 AMInsider Buying: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Major Shareholder Buys 850,000 Shares of Stockamericanbankingnews.com - May 14 at 4:14 AMBrokers Issue Forecasts for 4D Molecular Therapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:FDMT)americanbankingnews.com - May 14 at 2:54 AMAndreas Halvorsen's Firm Packs Further Into 4D Molecular Therapeuticsfinance.yahoo.com - May 12 at 6:48 PM4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up on Insider Buying Activitymarketbeat.com - May 12 at 10:34 AM4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Forecasted to Earn Q2 2023 Earnings of ($0.61) Per Sharemarketbeat.com - May 12 at 8:36 AM4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Brokeragesmarketbeat.com - May 12 at 5:12 AM4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Holdings Decreased by SG Americas Securities LLCmarketbeat.com - May 12 at 4:33 AM4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meetingfinance.yahoo.com - May 11 at 12:45 PM4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlightsfinance.yahoo.com - May 10 at 4:15 PM12,036 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Bought by Mitsubishi UFJ Kokusai Asset Management Co. Ltd.marketbeat.com - May 10 at 4:43 AM4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Sharesfinance.yahoo.com - May 9 at 7:53 PM4D Molecular Therapeutics (FDMT) to Release Quarterly Earnings on Wednesdayamericanbankingnews.com - May 9 at 9:08 AM4D Molecular Therapeutics (FDMT) Set to Announce Quarterly Earnings on Wednesdayamericanbankingnews.com - May 9 at 8:16 AM4D Molecular Therapeutics, Inc. (FDMT) Surges 5.4%: Is This an Indication of Further Gains?finance.yahoo.com - May 8 at 8:35 AM4D Molecular Therapeutics prices $120M share offeringseekingalpha.com - May 5 at 7:52 AM4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stockfinance.yahoo.com - May 4 at 9:50 PMHC Wainwright & Co. Reiterates 4D Molecular Therapeutics (FDMT) Buy Recommendationmsn.com - April 28 at 5:48 PMH.C. Wainwright Sticks to Their Buy Rating for 4D Molecular Therapeutics (FDMT)markets.businessinsider.com - April 28 at 7:45 AM4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Insider Sells $75,000.00 in Stockamericanbankingnews.com - April 28 at 5:50 AMInsider Selling: 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Director Sells $100,250.00 in Stockamericanbankingnews.com - April 28 at 5:50 AM4D Molecular Therapeutics Sinks on Latest Drug Trialmsn.com - April 27 at 4:44 PM4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023finance.yahoo.com - April 27 at 9:51 AM4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophyfinance.yahoo.com - April 24 at 8:30 AMAevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor Hfinance.yahoo.com - April 24 at 8:30 AM4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $34.13 Average PT from Analystsamericanbankingnews.com - April 24 at 5:28 AMAllspring Global Investments Holdings LLC Sells 8,190 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)marketbeat.com - April 20 at 4:19 AM4D Molecular Therapeutics (NASDAQ:FDMT) Trading 6.4% Higher americanbankingnews.com - April 19 at 6:54 AMFY2024 EPS Estimates for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Boosted by SVB Leerinkamericanbankingnews.com - April 18 at 2:42 AMFY2024 Earnings Forecast for 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Issued By SVB Leerinkmarketbeat.com - April 17 at 2:36 AMSVB Securities Lowers 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $13.00americanbankingnews.com - April 16 at 3:30 AM4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Down on Analyst Downgradeamericanbankingnews.com - April 15 at 1:20 AM4D Molecular Therapeutics, Inc. (FDMT) Soars 11.2%: Is Further Upside Left in the Stock?finance.yahoo.com - April 14 at 7:46 AMSVB Securities Maintains 4D Molecular Therapeutics (FDMT) Market Perform Recommendationmsn.com - April 13 at 9:25 PMSVB Securities Maintains Market Perform Rating for 4D Molecular Therapeutics: Here's What You Need To Knowmarkets.businessinsider.com - April 13 at 4:24 PMThe Latest Analyst Ratings for 4D Molecular Therapeuticsmarkets.businessinsider.com - April 13 at 4:24 PM4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officerfinance.yahoo.com - April 13 at 10:13 AMIs 4D Molecular Therapeutics (NASDAQ:FDMT) In A Good Position To Invest In Growth?finance.yahoo.com - April 12 at 9:33 AM Get 4D Molecular Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ALEC News EDIT News ITOS News NVAX News HLVX News AMAM News MESO News AUTL News VYGR News AGEN News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:FDMT) was last updated on 6/7/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 4D Molecular Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.